GB2448224B - Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent - Google Patents

Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent

Info

Publication number
GB2448224B
GB2448224B GB0805991A GB0805991A GB2448224B GB 2448224 B GB2448224 B GB 2448224B GB 0805991 A GB0805991 A GB 0805991A GB 0805991 A GB0805991 A GB 0805991A GB 2448224 B GB2448224 B GB 2448224B
Authority
GB
United Kingdom
Prior art keywords
reduction
effects
pharmaceutical composition
orally administered
administered pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB0805991A
Other languages
English (en)
Other versions
GB2448224A (en
GB0805991D0 (en
Inventor
Maryka Quik
Donato Di Monte
J William Langston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parkinsons Institute
Original Assignee
Parkinsons Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parkinsons Institute filed Critical Parkinsons Institute
Priority to GB0912941A priority Critical patent/GB2461412B/en
Priority to GB1008749A priority patent/GB2468424B/en
Publication of GB0805991D0 publication Critical patent/GB0805991D0/en
Publication of GB2448224A publication Critical patent/GB2448224A/en
Application granted granted Critical
Publication of GB2448224B publication Critical patent/GB2448224B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
GB0805991A 2007-04-02 2008-04-02 Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent Expired - Fee Related GB2448224B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB0912941A GB2461412B (en) 2007-04-02 2008-04-02 Methods and compositions for reduction of side effects of therapeutic treatments
GB1008749A GB2468424B (en) 2007-04-02 2008-04-02 Methods and compositions for reduction of side effects of therapeutic treatments

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90963707P 2007-04-02 2007-04-02
US95629607P 2007-08-16 2007-08-16
US95665707P 2007-08-17 2007-08-17

Publications (3)

Publication Number Publication Date
GB0805991D0 GB0805991D0 (en) 2008-05-07
GB2448224A GB2448224A (en) 2008-10-08
GB2448224B true GB2448224B (en) 2010-09-01

Family

ID=39409946

Family Applications (2)

Application Number Title Priority Date Filing Date
GB0805991A Expired - Fee Related GB2448224B (en) 2007-04-02 2008-04-02 Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent
GB0912941A Expired - Fee Related GB2461412B (en) 2007-04-02 2008-04-02 Methods and compositions for reduction of side effects of therapeutic treatments

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB0912941A Expired - Fee Related GB2461412B (en) 2007-04-02 2008-04-02 Methods and compositions for reduction of side effects of therapeutic treatments

Country Status (11)

Country Link
US (8) US7718677B2 (enExample)
EP (4) EP2322168A1 (enExample)
JP (3) JP2010523587A (enExample)
KR (2) KR20110075044A (enExample)
CN (2) CN101772346B (enExample)
AU (1) AU2008232453B8 (enExample)
CA (1) CA2682323A1 (enExample)
ES (1) ES2521494T3 (enExample)
GB (2) GB2448224B (enExample)
IL (2) IL201269A (enExample)
WO (1) WO2008122049A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US8058291B2 (en) * 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
EP2322168A1 (en) * 2007-04-02 2011-05-18 Parkinson's Institute Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
US9463190B2 (en) * 2008-03-31 2016-10-11 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
EP2300012A4 (en) * 2008-05-23 2011-07-06 Univ South Florida METHOD FOR TREATING PERIPHERAL SENSORY NERVE LOSS WITH COMPOUNDS WITH NICOTIC ACIDYLCHOLINE RECEPTOR EFFECT
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
EP2233134A1 (en) 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties
JO3250B1 (ar) * 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
US8741343B2 (en) 2009-12-02 2014-06-03 Adamas Pharmaceuticals, Inc. Method of administering amantadine prior to a sleep period
WO2011069051A1 (en) 2009-12-04 2011-06-09 Caliper Life Sciences, Inc. Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions
WO2012021629A2 (en) * 2010-08-11 2012-02-16 Philadelphia Health & Education Corporation Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
CN103180321A (zh) 2010-09-23 2013-06-26 Abbvie公司 氮杂金刚烷衍生物的一水合物
US20140017303A1 (en) * 2010-11-01 2014-01-16 Intec Pharma Ltd. Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms
MX2013008704A (es) * 2011-01-27 2013-08-21 Novartis Ag Uso de activadores del receptor de acetil-colina nicotinico alfa-7.
MX2013010698A (es) * 2011-03-18 2014-02-17 Novartis Ag Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson.
EP2729148A4 (en) * 2011-07-06 2015-04-22 Parkinson S Inst COMPOSITIONS AND METHOD FOR THE TREATMENT OF SYMPTOMS IN PATIENTS WITH MORBUS PARKINSON
WO2014134221A1 (en) * 2013-02-26 2014-09-04 Azhir Ari Compositions and methods for treatment in parkinson's disease patients
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US20150313891A1 (en) * 2014-05-02 2015-11-05 Abbvie Inc. Neuronal nicotinic agonists and methods of use
CA2946434C (en) * 2014-06-18 2021-07-06 Eli Lilly And Company Transdermal formulations of pergolide and uses thereof
CN111956803B (zh) * 2014-10-20 2025-10-31 奥伊斯特普安生物制药公司 治疗眼部病状的方法
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
JP2018511127A (ja) 2015-03-12 2018-04-19 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 渇望入力及び支援システム
CN106138061B (zh) * 2015-04-03 2019-06-04 中国人民解放军第三军医大学第三附属医院 预防或减弱肺纤维化的复合物及其制剂和用途
US10292977B2 (en) 2016-04-11 2019-05-21 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
US10143687B2 (en) 2016-04-11 2018-12-04 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
CA3049116A1 (en) * 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Methods and devices for treating levodopa induced dyskinesia
MX2020002078A (es) 2017-08-24 2020-09-21 Adamas Pharma Llc Composiciones de amantadina, preparaciones de estas y métodos de uso.
AU2019279884B2 (en) 2018-05-29 2025-01-30 Morningside Venture Investments Limited Drug delivery methods and systems
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
WO2020227646A1 (en) * 2019-05-09 2020-11-12 Apkarian Technologies Llc Methods and compositions for treating pain
FR3106978B1 (fr) 2020-02-11 2024-04-26 Olivier Petitjean Utilisation d'une molecule inhibitrice de la production de ros d'origine mitochondriale telle que l'anethole trithione pour traiter la maladie de parkinson
CA3230630A1 (en) * 2021-09-08 2023-03-16 Curtis SWIFT Analytical methods of assessing cytisine purity
WO2023057650A1 (en) 2021-10-10 2023-04-13 Centre Hospitalier Universitaire Vaudois (Chuv) A method for predicting side effects of drugs and vaccines

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662920A (en) * 1993-07-26 1997-09-02 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
WO1997034605A1 (en) * 1996-03-21 1997-09-25 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
WO1999066916A1 (en) * 1998-06-22 1999-12-29 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US20020002189A1 (en) * 1999-04-14 2002-01-03 Steve Smith Nicotine therapy method and oral carrier for assuaging tobacco-addiction
WO2002076211A1 (en) * 2001-03-26 2002-10-03 Smithkline Beecham Corporation Nicotine-containing oral dosage form
WO2003026655A1 (en) * 2001-09-27 2003-04-03 Pharmacia Ab New formulations and use thereof
US20030119879A1 (en) * 2001-10-15 2003-06-26 Thomas Landh Nicotine and chocolate compositions
WO2003061656A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
WO2007104575A2 (en) * 2006-03-16 2007-09-20 Niconovum Ab Stable lozenge compositions providing rapid release of nicotine
WO2007133141A1 (en) * 2006-05-16 2007-11-22 Mcneil Ab Coated pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US77276A (en) * 1868-04-28 Improvement in spring and body braces for vehicles
US113452A (en) * 1871-04-04 Improvement in table-leaf supports
US166159A (en) * 1875-07-27 Improvement in calcining-kilns
US3845217A (en) * 1972-11-16 1974-10-29 Helsingborg L Ab Buffered smoking substitute compositions
US4321387A (en) 1980-03-21 1982-03-23 Philip Morris, Incorporated Process for the preparation of optically active nicotine analogs
US4590278A (en) 1981-01-29 1986-05-20 Philip Morris Incorporated Nicotine analogs
US4442292A (en) 1981-01-29 1984-04-10 Philip Morris Incorporated Optically active nicotine analogs and process for their preparation
US4452984A (en) 1981-01-29 1984-06-05 Philip Morris, Inc. Optically active nicotine analogs and process for their preparation
US4332945A (en) 1981-01-29 1982-06-01 Philip Morris, Incorporated Optically active nicotine analogs and process for their preparation
GB8301659D0 (en) * 1983-01-21 1983-02-23 Leo Ab Smoking substitutes
GB8317576D0 (en) * 1983-06-29 1983-08-03 Shaw A S W Consumer tobacco products
US4953572A (en) * 1985-04-25 1990-09-04 Rose Jed E Method and apparatus for aiding in the reduction of incidence of tobacco smoking
US4920989A (en) * 1985-04-25 1990-05-01 Regents Of The University Of California Method and apparatus for aiding in the reduction of incidence of tobacco smoking
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
DE3639418A1 (de) * 1986-11-18 1988-06-09 Forschungsgesellschaft Rauchen Nikotinhaltiges mittel
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US5073380A (en) 1987-07-27 1991-12-17 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
ATE122353T1 (de) 1987-10-05 1995-05-15 Yamanouchi Pharma Co Ltd Heterozyklische spiroverbindungen und ihre herstellung.
IE62662B1 (en) 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
US5525351A (en) * 1989-11-07 1996-06-11 Dam; Anders Nicotine containing stimulant unit
US5512306A (en) * 1992-06-19 1996-04-30 Pharmica Ab Smoking substitute
PT100525B (pt) 1991-05-29 1999-10-29 Abbott Lab Azaspiranos substituidos imunomodulares, seu uso e composicoes farmaceuticas que os contem
GB9200047D0 (en) * 1992-01-03 1992-02-26 Univ Alberta Nicotine-containing nasal spray
US5242934A (en) 1992-03-02 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5212188A (en) 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5227391A (en) 1992-04-10 1993-07-13 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5232933A (en) 1992-05-21 1993-08-03 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5248690A (en) 1992-07-07 1993-09-28 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5703100A (en) 1994-11-10 1997-12-30 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
AU7125096A (en) 1995-09-22 1997-04-09 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
JPH11512443A (ja) 1995-09-22 1999-10-26 ノボ ノルディスク アクティーゼルスカブ 新規な置換アザ環式またはアザ二環式化合物
EP0874818B1 (en) 1995-11-17 2003-05-21 MERCK & CO. INC. Novel substituted aryl compounds useful as modulators of acetylcholine receptors
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
GB9614902D0 (en) 1996-07-16 1996-09-04 Rhodes John Sustained release composition
US6020335A (en) 1997-02-06 2000-02-01 Pfizer Inc (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
AU741821B2 (en) 1997-03-11 2001-12-13 Arakis Limited Dosage forms comprising separate portions of R- and S-enantiomers
FR2761072B1 (fr) 1997-03-20 1999-04-23 Synthelabo Derives de 2,3-dihydrofuro[3,2-b]pyridine, leur preparation et leur application en therapeutique
US5977131A (en) 1997-04-09 1999-11-02 Pfizer Inc. Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
ZA984637B (en) 1997-05-30 1998-12-21 Neurosearch As Spiro-quinuclidine derivatives their preparation and use
EE04057B1 (et) 1997-05-30 2003-06-16 Neurosearch A/S 8-asabitsüklo[3,2,1]okt-2-eeni ja -oktaani derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
ZA984638B (en) 1997-05-30 1998-12-11 Neurosearch As Azacyclooctane and heptane derivatives their preparation and use
WO1998054182A1 (en) 1997-05-30 1998-12-03 Neurosearch A/S 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS
FR2765874B1 (fr) 1997-07-09 1999-08-13 Synthelabo Derives de 6-pyrrolidin-2-ylpyrindines, leur preparation et leur application en therapeutique
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
US6034079A (en) 1997-08-11 2000-03-07 University Of South Florida Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
JP4570773B2 (ja) 1997-10-27 2010-10-27 ニューロサーチ、アクティーゼルスカブ ニコチン性アセチルコリンレセプターに於けるコリン作動性リガンドとしてのヘテロアリールジアザシクロアルカン
JP2001522846A (ja) 1997-11-05 2001-11-20 ニューロサーチ、アクティーゼルスカブ アザ環−エーテル誘導体及びこれをニコチン性ａｃｈレセプターモジュレーターとして使用する方法
US6057446A (en) 1998-04-02 2000-05-02 Crooks; Peter Anthony Certain 1-aza-tricyclo [3.3.1-13,7 ] decane compounds
EP0955301A3 (en) 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
US6211194B1 (en) * 1998-04-30 2001-04-03 Duke University Solution containing nicotine
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
US6365182B1 (en) 1998-08-12 2002-04-02 Cima Labs Inc. Organoleptically pleasant in-mouth rapidly disintegrable potassium chloride tablet
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
PT1107965E (pt) 1998-08-25 2004-10-29 Ortho Mcneil Pharm Inc Eteres e tioeteres de piridilo como ligantes para receptores de acetilcolina nicotinica e as suas aplicacoes terapeuticas
US6262124B1 (en) 1998-10-22 2001-07-17 Gary Maurice Dull Pharmaceutical compositions and methods for use
NZ510287A (en) 1998-11-27 2003-05-30 Neurosearch As 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives useful as cholinergic ligands at the nicotinic acetyl choline receptor
FR2786769B1 (fr) 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
FR2786770B1 (fr) 1998-12-04 2001-01-19 Synthelabo Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique
DE69939498D1 (de) 1998-12-16 2008-10-16 Univ South Florida Exo-S-Mecamylamin-Formulierung
CA2361525C (en) 1999-01-29 2009-12-08 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
ATE245153T1 (de) 1999-04-26 2003-08-15 Neurosearch As Heteroaryl-diazacycloalkane, ihre herstellung und verwendung
DE60008866T2 (de) 1999-05-04 2005-01-27 Neurosearch A/S Heteroaryl diazabicycloalkene, deren herstellung und verwendung
US20040229908A1 (en) 1999-07-13 2004-11-18 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
US20080138399A1 (en) * 1999-07-16 2008-06-12 Aradigm Corporation Dual release nicotine formulations, and systems and methods for their use
US6799576B2 (en) * 1999-07-16 2004-10-05 Aradigm Corporation System for effecting smoking cessation
US20080138294A1 (en) * 1999-07-16 2008-06-12 Igor Gonda Systems and methods for effecting cessation of tobacco use
US20080138398A1 (en) * 1999-07-16 2008-06-12 Aradigm Corporation Dual release nicotine formulations, and systems and methods for their use
US8256433B2 (en) * 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2798065B1 (fr) * 1999-09-02 2003-09-05 Assist Publ Hopitaux De Paris Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson
SE9903998D0 (sv) 1999-11-03 1999-11-03 Astra Ab New compounds
JP2001261652A (ja) 2000-03-21 2001-09-26 Suntory Ltd 二置換イミノヘテロサイクリック化合物
US6489025B2 (en) 2000-04-12 2002-12-03 Showa Denko K.K. Fine carbon fiber, method for producing the same and electrically conducting material comprising the fine carbon fiber
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
WO2002002081A1 (en) 2000-07-05 2002-01-10 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and methods of using same
GB0022084D0 (en) * 2000-09-08 2000-10-25 Univ Aberdeen Treatment of multiply antibiotic-resistant organisms
WO2002030392A2 (en) 2000-10-12 2002-04-18 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
SE0102197D0 (sv) 2001-06-20 2001-06-20 Pharmacia Ab New product and use and manufacture thereof
US20030087937A1 (en) 2001-10-15 2003-05-08 Nils-Olof Lindberg Nicotine and cocoa powder compositions
US20040037879A1 (en) * 2001-11-02 2004-02-26 Adusumilli Prasad S. Oral controlled release forms useful for reducing or preventing nicotine cravings
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
SE0104388D0 (sv) 2001-12-27 2001-12-27 Pharmacia Ab New formulation and use and manufacture thereof
US6852741B2 (en) 2001-12-31 2005-02-08 University Of Florida Compositions and methods for treatment of neurological disorders
US20030159702A1 (en) * 2002-01-21 2003-08-28 Lindell Katarina E.A. Formulation and use manufacture thereof
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US7767698B2 (en) 2002-06-03 2010-08-03 Mcneil Ab Formulation and use thereof
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US20040052851A1 (en) * 2002-09-16 2004-03-18 Graff Allan H. Modified release oral dosage form
ATE359075T1 (de) 2002-12-20 2007-05-15 Niconovum Ab Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
SE0301320D0 (sv) 2003-05-06 2003-05-06 Astrazeneca Ab Positive modulators of nicotinic acetylcholine receptors
US20050159419A1 (en) * 2003-05-14 2005-07-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
US7149574B2 (en) * 2003-06-09 2006-12-12 Palo Alto Investors Treatment of conditions through electrical modulation of the autonomic nervous system
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
MXPA06002609A (es) * 2003-09-08 2006-06-05 Pfizer Health Ab Formulaciones de nicotina y uso de las mismas.
US20050113452A1 (en) * 2003-10-20 2005-05-26 Moshe Flashner-Barak Composition and dosage form for sustained effect of levodopa
US20050266032A1 (en) 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
CN1332667C (zh) * 2004-05-26 2007-08-22 中国科学院生物物理研究所 一种抗帕金森症（pd）复合制剂
AU2005319248A1 (en) 2004-12-22 2006-06-29 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
EP1942869A2 (en) 2005-11-04 2008-07-16 Eastman Chemical Company Carboxyalkyl cellulose esters for sustained delivery of pharmaceutically active substances
US7958887B2 (en) * 2006-03-10 2011-06-14 Aradigm Corporation Nozzle pore configuration for intrapulmonary delivery of aerosolized formulations
EP2322168A1 (en) * 2007-04-02 2011-05-18 Parkinson's Institute Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662920A (en) * 1993-07-26 1997-09-02 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
WO1997034605A1 (en) * 1996-03-21 1997-09-25 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
WO1999066916A1 (en) * 1998-06-22 1999-12-29 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US20020002189A1 (en) * 1999-04-14 2002-01-03 Steve Smith Nicotine therapy method and oral carrier for assuaging tobacco-addiction
WO2002076211A1 (en) * 2001-03-26 2002-10-03 Smithkline Beecham Corporation Nicotine-containing oral dosage form
WO2003026655A1 (en) * 2001-09-27 2003-04-03 Pharmacia Ab New formulations and use thereof
US20030119879A1 (en) * 2001-10-15 2003-06-26 Thomas Landh Nicotine and chocolate compositions
WO2003061656A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
WO2007104575A2 (en) * 2006-03-16 2007-09-20 Niconovum Ab Stable lozenge compositions providing rapid release of nicotine
WO2007133141A1 (en) * 2006-05-16 2007-11-22 Mcneil Ab Coated pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Nicotine affects striatal glutamergic function in 6-OHDA lesioned rats", C.K. Meshul et al, Advances in behavioural Biology, (2003) 54 (Basal Ganglia VI), 589-598 *
"Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys", M.Quik et al, Annals of Neurology, (2007), 62(6), 588-596 *

Also Published As

Publication number Publication date
AU2008232453B8 (en) 2011-07-21
US20100159004A1 (en) 2010-06-24
US20100029723A1 (en) 2010-02-04
HK1147951A1 (en) 2011-08-26
EP1977746A1 (en) 2008-10-08
GB2461412B (en) 2010-09-29
EP2322166A1 (en) 2011-05-18
JP2010523587A (ja) 2010-07-15
CA2682323A1 (en) 2008-10-09
GB2448224A (en) 2008-10-08
US7718677B2 (en) 2010-05-18
JP2016020385A (ja) 2016-02-04
AU2008232453A1 (en) 2008-10-09
GB0912941D0 (en) 2009-09-02
CN103977003A (zh) 2014-08-13
GB2461412A (en) 2010-01-06
AU2008232453B2 (en) 2011-06-23
IL232200A0 (en) 2014-05-28
GB0805991D0 (en) 2008-05-07
US20100166735A1 (en) 2010-07-01
EP2322167A1 (en) 2011-05-18
JP2013155209A (ja) 2013-08-15
HK1135037A1 (en) 2010-05-28
KR101122469B1 (ko) 2012-07-12
EP1977746B1 (en) 2014-07-30
HK1145978A1 (en) 2011-05-13
CN101772346B (zh) 2014-05-07
US20160235732A1 (en) 2016-08-18
US20100158895A1 (en) 2010-06-24
ES2521494T3 (es) 2014-11-12
US20100196463A1 (en) 2010-08-05
US20110077276A1 (en) 2011-03-31
KR20110075044A (ko) 2011-07-05
AU2008232453A8 (en) 2011-07-21
US20080260825A1 (en) 2008-10-23
IL201269A0 (en) 2010-05-31
EP1977746B8 (en) 2014-09-24
IL201269A (en) 2014-05-28
KR20100045406A (ko) 2010-05-03
CN101772346A (zh) 2010-07-07
EP2322168A1 (en) 2011-05-18
WO2008122049A2 (en) 2008-10-09
WO2008122049A3 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
GB2448224B (en) Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent
IL205360A0 (en) Methods, kits, and compositions for administering pharmaceutical compounds
SI2046298T1 (sl) Farmacevtska odmerna oblika, ki vsebuje farmacevtsko sprejemljiv solubilizirni sestavek
IL206159A0 (en) Oral pharmaceutical dosage forms
IL193727A0 (en) Dosage forms for administering combinations of drugs
EP2112925A4 (en) SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
IL199472A0 (en) Non-effervescent, orally disintegrating solid pharmaceutical dosage forms, processes for the preparation of the same and uses thereof
IL199191A0 (en) Modified release ibuprofen solid oral dosage form
IL184126A0 (en) Solid, orally applicable pharmaceutical administration forms containing rivaroxaban having modified release
CO6440564A2 (es) Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
GB0703507D0 (en) Solid pharmaceutical dose
IL185390A0 (en) A solid pharmaceutical dosage formulation
PL2457562T3 (pl) Stałe postacie dawkowania leku o zmodyfikowanym uwalnianiu o kinetyce rzędu zerowego
ZA200810164B (en) Sustained release pharmaceutical dosage form containing phenylphrine
ZA201100615B (en) Appetising medicament for oral administration in solid form
EP2226071A4 (en) COMPOSITIONS FOR ORAL ADMINISTRATION
TW200806282A (en) Solid dosage formulations
JP2009537554A5 (enExample)
ZA201105572B (en) Pharmaceutical composition for oral administration
EP2263637A4 (en) MEDICINAL PREPARATION FOR ORAL ADMINISTRATION
EP2206519A4 (en) MEDICINAL PREPARATION FOR ORAL ADMINISTRATION
GB2455875B (en) A process for the preparation of an orally administered unit dose tablet
GB0703674D0 (en) A Process For The Preparation of an Orally Administered Unit Dose Tablet
WO2008060546A3 (en) Oral formulations
ZA201102405B (en) Pharmaceutical composition for oral administration

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20160402